Multiple Myeloma With Amplification of Chr1q: Therapeutic Opportunity and Challenges

Multiple myeloma (MM) is an incurable plasma cell malignancy with a heterogeneous genetic background. Each MM subtype may have its own therapeutic vulnerabilities, and tailored therapy could improve outcomes. However, the cumulative frequency of druggable targets across patients is very low, which has precluded the widespread adoption of precision therapy for patients with MM. Amplification of the long arm of chromosome 1 (Amp1q) is one of the most frequent genetic alterations observed in patients with MM, and its presence predicts inferior outcomes in the era of proteasome inhibitors and immunomodulatory agents. Therefore, establishing precision medicine for MM patients with Amp1q stands to benefit a large portion of patients who are otherwise at higher risk of relapse. In this article, we review the prevalence and clinical significance of Amp1q in patients with MM, its pathogenesis and therapeutic vulnerabilities, and discuss the opportunities and challenges for Amp1q-targeted therapy.

Abstract licence: CC BY

1. 57.

   Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients · 2017

2. 64.

   A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis · 2018

3. 66.

   Genomic patterns of progression in smoldering multiple myeloma · 2018

4. 71.

   Multiple myeloma immunoglobulin lambda translocations portend poor prognosis · 2019

5. 74.

   Genomic landscape and chronological reconstruction of driver events in multiple myeloma · 2019

6. 78.

   Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone · 2019

7. 93.
   Corrected

   MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents · 2020

8. 97.

   Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities · 2021

9. 98.

   Targeting MCL-1 in cancer: current status and perspectives · 2021

10. 99.

    Chromosome 1q21 abnormalities in multiple myeloma · 2021

103 more references, whose wording the paper’s licence keeps private.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.